J&J’s Cypher gets heart attack label in EU
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis gains CE mark Aug. 27 allowing the firm to promote its Cypher Select Plus sirolimus-eluting stent in Europe as a treatment for acute myocardial infarction. The clearance is based primarily on data from the 712-patient TYPHOON trial that showed Cypher to have a statistically significant advantage over bare-metal stents (7.3% v. 14.3%) for heart attack patients in a composite target vessel failure endpoint measure. Even after the TYPHOON data was published in the New England Journal of Medicine in 2006, however, cardiologists remained cautious about use of drug-eluting stents as a primary AMI treatment, noting the challenge of assessing during an emergent procedure whether the patient is likely to comply with a long-term anti-clotting medication regime that may be necessary to prevent a late stent thrombosis event (1"The Gray Sheet" Sept. 18, 2006, p. 8). Cordis has no plans to bring Cypher Select Plus to the U.S., where AMI remains an off-label indication
You may also be interested in...
In An Emergency, Value Of Drug-Eluting Stents Still Questionable, Docs Say
More data is needed before drug-eluting stents should be considered for routine use as part of emergency treatment for a heart attack, according to an editorial in the Sept. 14 New England Journal of Medicine
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.